4.4 Article

In Vivo MicroRNA Detection and Quantitation in Cerebrospinal Fluid

期刊

JOURNAL OF MOLECULAR NEUROSCIENCE
卷 47, 期 2, 页码 243-248

出版社

HUMANA PRESS INC
DOI: 10.1007/s12031-012-9731-7

关键词

Schizophrenia; miRNA; Cerebrospinal fluid; Gene expression; Psychosis; Biomarker

资金

  1. National Institute of Health [R01MH079800, P50 MH080173-04, M01RR018535, UL1 RR025750]
  2. Eli Lilly
  3. Forest Research Institute
  4. Accera
  5. GE Healthcare

向作者/读者索取更多资源

Alterations in microRNA (miRNA) expression in postmortem brain tissue or peripheral blood have been linked to schizophrenia. Cerebrospinal fluid might provide an in vivo biomarker more directly reflecting functional changes in the brain. The goals of this study were to determine the feasibility of detecting miRNAs in cerebrospinal fluid and to compare miRNA levels in cerebrospinal fluid versus blood. Four healthy volunteers and four patients with psychotic disorders underwent a lumbar puncture and a blood draw. Expression of 378 validated miRNAs was assessed from each biofluid type for each subject using microarray technology. Five miRNAs were chosen for validation with quantitative polymerase chain reaction. A substantial number of miRNAs (n = 95) were exclusively or predominately detected in cerebrospinal fluid (CSF). Levels of 35 miRNAs detected in both CSF and blood samples in all subjects were poorly correlated. The investigation of miRNAs in CSF can help advance the understanding of psychiatric diseases and particularly schizophrenia.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据